Comorbidity prevalence and incidence in cancer survivors: a longitudinal All of Us study
-д хадгалсан:
| -д хэвлэсэн: | JNCI Cancer Spectrum vol. 9, no. 6 (Dec 2025) |
|---|---|
| Үндсэн зохиолч: | |
| Бусад зохиолчид: | , , , |
| Хэвлэсэн: |
Oxford University Press
|
| Нөхцлүүд: | |
| Онлайн хандалт: | Citation/Abstract Full Text - PDF |
| Шошгууд: |
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3268220836 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2515-5091 | ||
| 024 | 7 | |a 10.1093/jncics/pkaf093 |2 doi | |
| 035 | |a 3268220836 | ||
| 045 | 2 | |b d20251201 |b d20251231 | |
| 100 | 1 | |a Lee, Jung Ae |u Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, United States | |
| 245 | 1 | |a Comorbidity prevalence and incidence in cancer survivors: a longitudinal All of Us study | |
| 260 | |b Oxford University Press |c Dec 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a Background Comorbidities worsen cancer survival, but patterns of preexisting and new-onset comorbidities among cancer survivors are unknown. Methods We investigated self-reported and clinically diagnosed comorbidity among cancer survivors in the All-of-Us program’s national database. Eight highly prevalent comorbidities were identified using self-reported data from the personal health history survey among cancer survivors (n = 20 534) and noncancer adults (n = 113 628) and validated among cancer survivors (n = 26 978) using data from electronic health records (EHRs). Among 5-year survivors (n = 9174) documented in EHR, we further estimated the incidence of new-onset comorbidities. Results The most prevalent comorbidities identified in personal health history data were hypertension (40.5%), osteoarthritis (28.4%), depression (28.0%), and obesity (23.2%). EHR data identified preexisting comorbidities: hypertension (43.3%), osteoarthritis (29.4%), depression (19.4%), and obesity (19.1%). During 5-year survival, more than 50% of cancer survivors developed at least one new comorbidity, and more than 25% developed two or more. The onset of new comorbidities showed a sharp increase in the first-year postdiagnosis. Incidence rates varied by age, race, and ethnicity. Conclusion Future research is needed to develop effective strategies to prevent new-onset comorbidities during and after cancer treatment. | |
| 653 | |a Cancer | ||
| 653 | |a Comorbidity | ||
| 653 | |a Osteoarthritis | ||
| 653 | |a Electronic health records | ||
| 653 | |a Personal health | ||
| 653 | |a Medical treatment | ||
| 653 | |a Survivor | ||
| 653 | |a Hypertension | ||
| 700 | 1 | |a Pakpahan, Ratna |u Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St Louis, MO, United States | |
| 700 | 1 | |a Amante, Daniel J |u Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, United States | |
| 700 | 1 | |a Gerber, Ben S |u Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, MA, United States | |
| 700 | 1 | |a Yang, Lin |u Department of Cancer Epidemiology and Prevention Research, Cancer Care, Alberta, Canada | |
| 773 | 0 | |t JNCI Cancer Spectrum |g vol. 9, no. 6 (Dec 2025) | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3268220836/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3268220836/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch |